Bora Lim
Overview
Explore the profile of Bora Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
2401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alam R, Reva A, Edwards D, Lege B, Munoz-Arcos L, Reduzzi C, et al.
Cancer Discov
. 2025 Jan;
PMID: 39835789
Bone metastases can disseminate to secondary sites and promote breast cancer progression creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction...
2.
Morita D, Rosewell Shaw A, Biegert G, Porter C, Woods M, Vasileiou S, et al.
J Immunother Cancer
. 2024 Dec;
12(12).
PMID: 39653552
Background: Oncolytic adenoviruses (OAds) are the most clinically tested viral vectors for solid tumors. However, most clinically tested "Armed" OAds show limited antitumor effects in patients with various solid tumors...
3.
Lin Y, Wang J, Wang K, Bai S, Thennavan A, Wei R, et al.
Nature
. 2024 Nov;
636(8043):663-670.
PMID: 39567687
Aneuploid epithelial cells are common in breast cancer; however, their presence in normal breast tissues is not well understood. To address this question, we applied single-cell DNA sequencing to profile...
4.
Yam C, Patel M, Hill H, Sun R, Bassett Jr R, Kong E, et al.
Cancer Res Commun
. 2024 Oct;
4(10):2823-2834.
PMID: 39356138
Purpose: Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the...
5.
Hao X, Shen Y, Liu J, Alexander A, Wu L, Xu Z, et al.
Nat Cell Biol
. 2024 Sep;
26(11):1971-1983.
PMID: 39266726
Solid tumours induce systemic immunosuppression that involves myeloid and T cells. B cell-related mechanisms remain relatively understudied. Here we discover two distinct patterns of tumour-induced B cell abnormality (TiBA; TiBA-1...
6.
Huang M, Lane D, Chang Sen L, Candelaria R, Kuerer H, Hunt K, et al.
Acad Radiol
. 2024 Aug;
31(12):4759-4771.
PMID: 39107186
Rationale And Objectives: Recent ICE3 trial of breast cryoablation for breast cancer demonstrated 98% success rate, similar to breast-conserving surgery. However, ICE3 and other published studies did not differentiate curative...
7.
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, et al.
Nat Commun
. 2024 Jul;
15(1):5621.
PMID: 38965214
No abstract available.
8.
Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, et al.
Cell Rep Med
. 2024 Jun;
5(6):101595.
PMID: 38838676
Luminal androgen receptor (LAR)-enriched triple-negative breast cancer (TNBC) is a distinct subtype. The efficacy of AR inhibitors and the relevant biomarkers in neoadjuvant therapy (NAT) are yet to be determined....
9.
Iwase T, Cohen E, Gao H, Alexander A, Kai M, Chiv V, et al.
Clin Cancer Res
. 2024 Apr;
30(11):2424-2432.
PMID: 38629963
Purpose: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy...
10.
Basho R, Zhao L, White J, Huo L, Bassett R, Mittendorf E, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300124.
PMID: 38484209
Purpose: The PI3K pathway is frequently altered in triple-negative breast cancer (TNBC). Limited cell line and human data suggest that TNBC tumors characterized as mesenchymal (M) and luminal androgen receptor...